These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32632925)

  • 21. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates.
    Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G
    Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polio endgame: the global switch from tOPV to bOPV.
    Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
    Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An economic analysis of poliovirus risk management policy options for 2013-2052.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
    Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
    PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
    Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC
    N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
    Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
    Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Risk Anal; 2021 Feb; 41(2):248-265. PubMed ID: 31960533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.
    Pan WK; Seidman JC; Ali A; Hoest C; Mason C; Mondal D; Knobler SL; Bessong P;
    Vaccine; 2019 Jan; 37(2):352-365. PubMed ID: 30442479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    Modlin JF; Bandyopadhyay AS; Sutter R
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.